Comparative research of clinical efficience of 3% TeTracycline ointment and 2% of mupirocin ointment in pyoderma therapy

Abstract

Pyodermas are infectious skin diseases, prevailing in morbidity patterns of all categories of RF military men. The optimal etiotropic substance for the treatment of pustular diseases is carried out, while taking into consideration the data on excitors’ sensitivity. Mupirocin is a topical antibacterial substance, which activity is equivalent to the activity of peroral antibiotics Target - Migrative evaluation of the efficiency of 3% of tetracycline ointment and 2% of mupirocin ointment (supirocin) in the treatment of patients with pyoderma. Маterial and methods. 60 patients with initial pyodermas were examined, before and after the course of treatment the bacteriological research of erosions’ secretion was performed. Patients were undergoing the monotherapy with topical antibacterial substance 2 times a day: 2% mupirocin ointment in the 1st group and - 3% of tetracycline ointment in the 2nd group. After the regress of eruptions terms and efficiency of the treatment were assessed. Results. The topical antibacterial therapy of pyodermas with 2% mupirocin ointment is more effective than with 3% tetracycline ointment, - 40 (100%) of patients against 16 (80%) of patients, (р < 0,01). The use of 2% mupirocin ointment allows to decrease considerably terms of treatment of patients with pustular skin diseases in comparison with application of 3% tetracycline ointment (8,1 ± 1,8 and 12,2 ± 3,2 days accordingly, р < 0,01). 2% mupirocin ointment has got high clinical efficiency and can be recommended for the therapy of patients with pyodermas.

Full Text

Сравнительное исследование клинической эффективности 3% тетрациклиновой мази и 2% мази мупироцина в терапии пиодермий
×

References

  1. Ki V., Rotstein C. Bacterial skin and soft tissue infections in adults: a review of their epidemiology, pathogenesis, diagnosis, treatment and site of care. Canad J Infect Med Microbiol 2008; 19: 173-84.
  2. Drygen M.S. Skin and soft tissue infection: microbiology and epidemiology. Int J Antimicrob Agents. 2009; 34: 2-7.
  3. Белькова Ю.А. Пиодермии в амбулаторной практике. Клин. микробиол. и антимикр. химиотер. 2005;7:255-270.
  4. May A.K. Skin and soft tissue infections. Surg Clin N Amer 2009; 89: 403-420.
  5. Moran G.J., Krishnadasan A., Gorwitz R.J. et al.; EMERGEncy ID Net Study Group. Methicillin-resistant S. aureus infections among patients in the emergency department. New Engl J Med 2006; 17, 355 (7): 666-74.
  6. Deleo F.R., Otto M., Kreiswirth B.N. et al. Community-associated meticillin-resistant Staphylococcus aureus. Lancet. 2010; 1; 375 (9725): 1557-68.
  7. Stevens D.L., Bisno A.L., Chambers H.F. et al. Practice guidelince for the diagnosis and management of skin and soft-tissue infection. Clinical Infectious Diseases. 2005; 41: 1373-406.
  8. Liu C. Bayer A., Cosgrov A.E. et al. Clinical practice guidelines by the infections diseases society of America for the treatment of methicillin-resistant Staphylococcus aureaus in adults and children. Clin Infect 2011; 52: e18-e55.
  9. Белькова Ю.А., Страчунский Л.С., Кречикова О.И. и др. Сравнительная эффективность 0,75% мази хлорамфеникола и 2% мази мупироцина при лечении в амбулаторных условиях взрослых пациентов с инфекциями кожи и мягких тканей. Клин. микробиол. и антимикр. химиотер. 2007; (1): 57-65.
  10. Sanders CJ, Bruijnzeel-Koomen CA. The practice guideline 'Bacterial skin infections' (first revision) from the Dutch College of General Practitioners; a response from the perspective of dermatology. Ned T Geneesk 2008; 19; 152 (29): 1604-5.
  11. Фельдман Ю.М., Миханева Л.Г., Шапиро А.В. и др. Количественное определение бактерий в клинических материалах. Лаб. дело 1984;(10): 616-619.

Statistics

Views

Abstract: 944

PDF (Russian): 484

Article Metrics

Metrics Loading ...

Dimensions

PlumX

Refbacks

  • There are currently no refbacks.

Copyright (c) 2012 SAMTSOV A.V., STATSENKO A.V., HAIRUTDINOV V.R., CHAPLYGIN A.V.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies